Merck KGaA

Merck KGaA sheds light on failed portion of phase 2 lupus trial

Merck KGaA has shed light on the failure in one lupus cohort, while pointing to secondary endpoint wins as proof that enpatoran still deserves a shot.

James Waldron Jun 12, 2025 9:41am

Protara gears up for next commercial steps—Chutes & Ladders

Jun 6, 2025 8:30am

An arrow incrementally going up stairs before pointing straight up Blue background

Merck KGaA posts tumor data ahead of showdown with Daiichi, Ono

May 28, 2025 8:45am

After setback, Merck KGaA shows data justifying lupus ph. 3 push

May 21, 2025 9:50am

German program matches lost NIH grants with pharma funders

Apr 7, 2025 10:50am

Three blocks displaying from left to right a person a handshake and another person

Merck KGaA pays $85M for global rights to Abbisko's tumor drug

Apr 1, 2025 7:40am